EHMT2 and Alzheimer disease: Because translational mechanisms ultimately determine function-related protein abundance or modification states24, we developed a new mechanism-based therapeutic for AD, i.e., MS1262, a brain-penetrant inhibitor of G9a, to block G9a-mediated translation of AD-related proteins.